Literature DB >> 21647642

Advances in syncope: with emphasis on reflex syncope.

John D Fisher1.   

Abstract

Syncope is a sudden transient loss of consciousness associated with loss of postural tone, caused by bradycardia, tachycardia, or abnormal autonomic reflexes. Pacing and implantable defibrillators treat but do not cure arrhythmias. Reflex syncope has remained a therapeutic challenge. Remarkably, recent advances in the treatment of the reflex syncopal syndromes are (1) the recognition that many pharmacologic and device-based treatments do not really work, (2) complex subdivisions among the reflex syncope types can be simplified, and (3) effective therapies are often common sense applications of behavioral modifications and physical maneuvers. Many of the treatments have been available for decades and have been supplemented by a renewed interest in the physiologic approach while maintaining a role for evidence-based pharmacologic and device-based therapy. Streamlined workups in dedicated syncope centers may be effective, both economically and therapeutically. In the long term, important advances in syncope are likely to come from the still embryonic field of genetics. Beyond genetic counseling, the greatest benefits lie in the future.

Entities:  

Mesh:

Year:  2011        PMID: 21647642     DOI: 10.1007/s10840-011-9579-8

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  53 in total

1.  Management of vasovagal syncope: controlling or aborting faints by leg crossing and muscle tensing.

Authors:  C T Paul Krediet; Nynke van Dijk; Mark Linzer; Johannes J van Lieshout; Wouter Wieling
Journal:  Circulation       Date:  2002-09-24       Impact factor: 29.690

2.  The expectation effect and cardiac pacing for refractory vasovagal syncope.

Authors:  Sachin Sud; David Massel; George J Klein; Peter Leong-Sit; Raymond Yee; Allan C Skanes; Lorne J Gula; Andrew D Krahn
Journal:  Am J Med       Date:  2007-01       Impact factor: 4.965

3.  Ivabradine in the treatment of orthostatic intolerance.

Authors:  Richard Sutton; Tushar Salukhe
Journal:  Europace       Date:  2011-03       Impact factor: 5.214

4.  Long-term follow-up results of tilt training therapy in patients with recurrent neurocardiogenic syncope.

Authors:  Tony Reybrouck; Hein Heidbüchel; Frans Van De Werf; Hugo Ector
Journal:  Pacing Clin Electrophysiol       Date:  2002-10       Impact factor: 1.976

Review 5.  Brugada syndrome.

Authors:  Charles Antzelevitch
Journal:  Pacing Clin Electrophysiol       Date:  2006-10       Impact factor: 1.976

6.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.

Authors: 
Journal:  N Engl J Med       Date:  1997-11-27       Impact factor: 91.245

7.  Dual-chamber pacing in the treatment of neurally mediated tilt-positive cardioinhibitory syncope : pacemaker versus no therapy: a multicenter randomized study. The Vasovagal Syncope International Study (VASIS) Investigators.

Authors:  R Sutton; M Brignole; C Menozzi; A Raviele; P Alboni; P Giani; A Moya
Journal:  Circulation       Date:  2000-07-18       Impact factor: 29.690

8.  Mechanism of syncope in patients with bundle branch block and negative electrophysiological test.

Authors:  M Brignole; C Menozzi; A Moya; R Garcia-Civera; L Mont; M Alvarez; F Errazquin; J Beiras; N Bottoni; P Donateo
Journal:  Circulation       Date:  2001-10-23       Impact factor: 29.690

9.  Effect of beta blockers on the time to first syncope recurrence in patients after a positive isoproterenol tilt table test.

Authors:  R Sheldon; S Rose; P Flanagan; M L Koshman; S Killam
Journal:  Am J Cardiol       Date:  1996-09-01       Impact factor: 2.778

10.  Cost implications of testing strategy in patients with syncope: randomized assessment of syncope trial.

Authors:  Andrew D Krahn; George J Klein; Raymond Yee; Jeffrey S Hoch; Allan C Skanes
Journal:  J Am Coll Cardiol       Date:  2003-08-06       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.